AMD Therapy: Where Are We Now and Where Are We Going?

Slides:

Advertisements

Similar presentations

Upfront Combination Therapy vs Step-Up Approach for PAH:

Advertisements

Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.

nAMD: Choosing the Best Treatment for your Patient

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

New Therapies for Hyperkalemia Across the Continuum of Care

At The Cutting Edge of Developments in the Management of Hyperkalemia

Clinical Trials to Real World:

The Patient Journey to Remission in MDD: A Collaborative Approach

REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

Ask the Onychomycosis Expert, Part 1

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

Case Challenges in Chronic Migraine

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

Induction Chemotherapy for Patients With High-Risk or Secondary AML

nAMD: Switching Therapies - what you need to know

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

New Data in nAMD: What Does the Future Hold?

A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.

Optimizing Management of Advanced Bladder Cancer

Talking to Patients About Diabetes Management

Multidisciplinary Perspectives on Interstitial Lung Diseases

Is it Time for a Paradigm Change in HIV Management?

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Next-Gen Psoriasis Therapies:

Updates on Anti-VEGF Therapy: Improving Durability and Predicting Response.

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

EHL Technologies in Hemophilia Care

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Mutational Testing to Select Novel Targeted Therapies in AML

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Advancing the Treatment of IBD With Biologics

Extraordinary Cases of VTE Prevention in Patients With Cancer

Improving Outcomes in Psoriatic Arthritis

Personalizing Management in the Care of Patients With Advanced Sarcoma

Management of Systematic Lupus Erythematosus

The Evolving Treatment Landscape in Atopic Dermatitis

Key Questions for nAMD Treatment Success

Developments in the Wet AMD Treatment Landscape

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

nAMD: Choosing the Best Treatment for your Patient

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

What You Didn't Know About AF and Renal Dysfunction

CAD and HF Often Coexist

Implications of Emerging Treatments for Beta-Thalassemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Patient Questions and Expert Answers in Psoriasis:

The Changing Field of Melanoma: Ipilimumab.

Critical Decision Points in Insomnia

Application of Biologics in IBD:

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Debates and Dilemmas, Part 1

Improving Adherence to Antiplatelet Therapy After an ACS Event

Clinical Challenges and Updates in Managing Seizure Clusters

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Program Goal. Program Goal Disclaimer Overview.

Educational Objectives

At the Crossroads of Coagulation

Tailoring Therapy in the Newly Diagnosed Patient With CLL

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Psoriatic Arthritis.

Presentation transcript:

AMD Therapy: Where Are We Now and Where Are We Going?

Program Goal

Anti-VEGF Agents for the Treatment of AMD

The CATT Study

The CATT Study: Safety Results Year 2

The CATT Study: Efficacy Results Year 2

The IVAN Study

The IVAN Study: Interim Results at Year 1

The VIEW1/2 Studies

The VIEW1/2 Study Results

Case 1: A Treatment-Naive Patient

Diagnostic Workup

Issues to Address

Considerations for Choosing Treatment

Dosing

Case 2: Patient With Treatment-Resistant AMD

Treatment Approaches

Future Developments

Future Developments

Abbreviations

References

References (cont)

References (cont)

References (cont)